Published in Lab Law Weekly, March 2nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Novartis.
Report 1: Novartis has received a positive opinion supporting European Union regulatory approval for Lucentis (ranibizumab) as a new treatment option for patients with the "wet" form of age-related macular degeneration (AMD), the leading cause of severe vision loss in people over age 50 in the western world.
The Committee for Medicinal Products for Human Use (CHMP), which reviews drug applications for all 25 countries in the European Union as well as Iceland...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.